Ποια είναι η τιμή για Redx Pharma Plc (REDX)

Η τιμή για Redx Pharma Plc (REDX) είναι $0.20410523

Ποια είναι η κεφαλαιοποίηση αγοράς για Redx Pharma Plc (REDX)

Η κεφαλαιοποίηση αγοράς για Redx Pharma Plc (REDX) είναι $793.94K

Redx Pharma Plc (REDX) Τιμή και Κεφαλαιοποίηση Αγοράς

Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.

Η τιμή για REDX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$1,399,514 $793.94K	NVDA	$5.444T	+685,682,424.19%
$1,152,716 $793.94K	AAPL	$4.484T	+564,765,451.96%
$1,071,118 $793.94K	GOOG	$4.166T	+524,787,034.13%
$951,240 $793.94K	MSFT	$3.700T	+466,053,503.27%
$729,739 $793.94K	AMZN	$2.839T	+357,530,880.33%

Η τιμή για REDX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$1,399,514 $793.94K